Quoin Pharmaceuticals, Ltd. Share Price

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/06/2024 BST 5-day change 1st Jan Change
0.6252 USD -8.89% Intraday chart for Quoin Pharmaceuticals, Ltd. -15.51% -87.25%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 2.49M 196M
Net income 2024 * -7M -551M Net income 2025 * -11M -866M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.18 x
P/E ratio 2025 *
-0.67 x
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 24.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.89%
1 week-15.51%
Current month-19.55%
1 month-17.74%
3 months-34.67%
6 months-85.48%
Current year-87.25%
More quotes
1 week
0.62
Extreme 0.62
0.76
1 month
0.62
Extreme 0.62
0.79
Current year
0.60
Extreme 0.6029
6.18
1 year
0.60
Extreme 0.6029
12.00
3 years
0.60
Extreme 0.6029
2 018.25
5 years
0.60
Extreme 0.6029
2 018.25
10 years
0.60
Extreme 0.6029
2 018.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 04/03/18
Founder 55 04/03/18
Director of Finance/CFO 60 31/10/21
Members of the board TitleAgeSince
Director/Board Member - 27/10/21
Director/Board Member 73 27/10/21
Director/Board Member 66 27/10/21
More insiders
Date Price Change Volume
17/06/24 0.6252 -8.89% 105,997
14/06/24 0.6862 -4.69% 44,426
13/06/24 0.72 +1.39% 35,273
12/06/24 0.7101 -3.90% 105,665
11/06/24 0.7389 -0.15% 38,787

Delayed Quote Nasdaq, June 17, 2024 at 09:00 pm

More quotes
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.6252 USD
Average target price
5.483 USD
Spread / Average Target
+777.05%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW